Development of Medicated Hair Growth Product Nyumo as a New Core Product

「Cumulative shipments of the core product 「ニューモ育毛剤」 exceeded 30 million units as of 17 February 2025. Strong orders for the pharmaceutical 「ニューZ」 through web advertising also contributed to an increase in subscription customers across the ニューモ brand.」

「Revenue from pharmaceuticals and quasi-drugs, including 「ニューモ育毛剤」, was ¥36,652 million, up 5.6% year on year. Cumulative shipments of 「ニューモ育毛剤」 exceeded 27 million units as of 4 June 2024. The medicated whitening gel 「DRcula (キュラ)」 and 「ラクトロン錠」 contributed to earnings as core products.」

「Revenue from pharmaceuticals and quasi-drugs, including 「ニューモ育毛剤」, was ¥27,986 million, up 9.7% year on year. Cumulative shipments of 「ニューモ育毛剤」 exceeded 26 million units as of 21 March 2024. The medicated whitening gel 「DRcula (キュラ)」 and 「ラクトロン錠」 contributed to earnings as core products. In addition, the pharmaceuticals 「ニューZ」 under the ニューモ brand and the Kampo medicine 「防風通聖散」 made increasingly significant contributions to revenue.」

「Revenue from pharmaceuticals and quasi-drugs, including 「ニューモ育毛剤」, was ¥18,918 million, up 15.6% year on year. Cumulative shipments of 「ニューモ育毛剤」 exceeded 25 million units as of 17 January 2024, and orders have remained firm.」

「Revenue from pharmaceuticals and quasi-drugs, including 「ニューモ育毛剤」, was ¥9,623 million, up 26.7% year on year. Cumulative shipments of 「ニューモ育毛剤」 exceeded 24 million units as of 20 November 2023, and orders have remained firm. The medicated whitening gel 「DRcula (キュラ)」 saw an increase in orders, particularly through web advertising, leading to an increase in subscription customers. In addition, the Company began promoting new products under the ニューモ brand, including the pharmaceutical 「ニューZ」 and 「ヘアパウダー」 containing artificial hair made from eggshell membrane.」

「Subscription customers for the core product 「ニューモ育毛剤」 numbered 434,527 (441,403 in the previous fiscal year, down 1.6% year on year), while new customer acquisition and the subscription continuation rate remained stable, contributing to Group-wide revenue and profit. Cumulative shipments of 「ニューモ育毛剤」 exceeded 22 million units as of 22 July 2023, and orders have remained firm.」

「Revenue from 「ニューモ育毛剤」 was ¥13,708 million, down 8.1% year on year, while subscription customers numbered 478,894, compared with 520,958 in the same period of the previous fiscal year. Stable levels of new customer acquisition and subscription continuation enabled the product to contribute to Group-wide revenue and profit. Cumulative shipments of 「ニューモ育毛剤」 exceeded 18 million units as of 24 December 2022, and orders have remained firm.」

「Revenue from 「ニューモⓇ育毛剤」 was ¥6,699 million, down 9.8% year on year, while subscription customers numbered 470,198. The recovery in new customer acquisition, together with the relatively high subscription continuation rate, has provided a foundation for Group-wide revenue and profit. Cumulative shipments of 「ニューモⓇ育毛剤」 exceeded 17 million units as of 5 November 2022, and orders have remained firm.」

「Revenue from 「ニューモⓇ育毛剤」 during the third quarter of the current consolidated cumulative period was ¥21,834 million. The number of subscription customers remained high at 467,335, and progress in repeat purchases contributed to higher Group-wide revenue and profit. Cumulative shipments of 「ニューモⓇ育毛剤」 exceeded 13 million units as of 5 April 2022, and orders have remained firm.」

「Revenue from 「ニューモⓇ育毛剤」 during the second quarter of the current consolidated cumulative period was ¥14,913 million. The number of subscription customers remained high at 520,958, and progress in repeat purchases contributed to higher Group-wide revenue and profit. Cumulative shipments of 「ニューモⓇ育毛剤」 exceeded 12 million units as of 17 February 2022, and orders have remained firm.」

「Revenue from 「ニューモⓇ育毛剤」 during the first quarter of the current consolidated cumulative period was ¥7,431 million. The number of subscription customers remained high at 543,602, and progress in repeat purchases contributed to higher Group-wide revenue and profit. Cumulative shipments of 「ニューモⓇ育毛剤」 exceeded 10 million units as of 15 November 2021.」

「「ニューモⓇ育毛剤」 focused on customer acquisition through television and web advertising as well as print media such as newspaper advertising, while repeat purchases by existing customers also increased. As a result, revenue for the current consolidated fiscal year was ¥26,763 million.」

「「ニューモⓇ育毛剤」 focused on customer acquisition through television and web advertising as well as print media such as newspaper advertising, while repeat purchases by existing customers also increased. As a result, revenue during the third quarter of the current consolidated cumulative period was ¥19,043 million.」

「「ニューモⓇ育毛剤」 successfully acquired customers at a very favorable CPO, particularly through television advertising, and generated revenue of ¥11,150 million during the second quarter of the current consolidated cumulative period. Revenue from 「ニューモⓇサプリメント」 was ¥1,818 million, and the increase in the percentage of customers purchasing it together with the hair-growth treatment contributed to higher average customer spending.」

「「ニューモⓇ育毛剤」 maintained its improving CPO trend across all media, including the internet, and achieved particularly efficient customer acquisition through television advertising. The percentage of customers purchasing 「ニューモⓇサプリメント」 at the same time also increased, contributing to higher average customer spending. In addition, the rate of subscription continuation, which is important for improving LTV, rose particularly for the second purchase. As a result, revenue from 「ニューモⓇ育毛剤」 during the first quarter of the current consolidated cumulative period had already exceeded revenue for the full previous fiscal year.」

「By the end of the third quarter of the current consolidated cumulative period, approximately 500,000 units of 「ニューモⓇ育毛剤」 had been shipped, driving revenue growth. The product made a significant contribution to both revenue and profit after successfully achieving a substantial increase in sales volume while maintaining the improving trend in CPO.」

「In particular, 160,000 units of the 「ニューモⓇ育毛剤」 hair-growth treatment were shipped during the second quarter of the current consolidated cumulative period, making it a major hit. The CPO for 「ニューモⓇ育毛剤」 during the second quarter of the current consolidated cumulative period improved by 23.9% compared with the CPO for 「タマゴサミンⓇ」 in the second quarter of the previous fiscal year, so the Company increased advertising expenses for 「ニューモⓇ育毛剤」, primarily for web advertising.」

「In particular, the medicated hair-growth treatment 「ニューモⓇ」, which reached 30,000 subscription customers during the first quarter of the current consolidated cumulative period, achieved very strong advertising investment efficiency. Accordingly, the Company increased the allocation of advertising expenses beyond its initial expectations, and the product is growing as a new core product following 「タマゴサミンⓇ」. From September through October, production could not keep pace with orders that exceeded expectations, resulting in advertising investment ahead of sales, and the product did not contribute to revenue during the first quarter of the current consolidated cumulative period. However, shipments began progressively in late November, and the product is expected to make a significant contribution to revenue from the second quarter onward.」